CJC-1295 Ipamorelin blend is a dual-peptide research compound combining two mechanistically distinct growth hormone secretagogues into a single lyophilized vial. Each compound in the CJC-1295 Ipamorelin blend targets a different receptor in the growth hormone axis, making the combination a well-studied model for examining how dual-pathway stimulation affects GH secretion patterns in research settings.
How Each Compound Works
CJC-1295 is a growth hormone-releasing hormone analog that stimulates the pituitary gland over an extended period, facilitating long-term GH signaling. Ipamorelin is a selective ghrelin receptor agonist that stimulates faster, more immediate pulses of GH release with limited interaction with stress-related hormones.
The reason they are studied together comes down to timing. Ipamorelin’s receptor-mediated activity is observed earlier in the response profile, potentially priming GH release, while CJC-1295’s prolonged receptor engagement sustains GH-related activity through continued stimulation of the GHRH pathway. Together they produce what researchers describe as both a baseline and pulsatile release pattern — closer to the body’s natural GH secretion rhythm than either compound achieves alone.
Where the Research Stands
CJC-1295 has been studied in human trials. After a single injection, mean plasma GH concentrations increased 2 to 10-fold for 6 or more days, and IGF-I concentrations increased 1.5 to 3-fold for 9 to 11 days. No serious adverse reactions were reported. Ipamorelin has been noted for its selectivity — unlike older compounds in its class, it does not appear to significantly stimulate cortisol or prolactin in preclinical models, which has made it a preferred subject for GH axis research.
About the CJC-1295 Ipamorelin Blend
The CJC-1295 Ipamorelin blend is one of the most studied dual-peptide combinations in growth hormone axis research. By combining a GHRH analog with a ghrelin receptor agonist, the CJC-1295 Ipamorelin blend allows researchers to examine complementary receptor pathways simultaneously under controlled experimental conditions. Each vial contains equal amounts of both compounds for consistent dosing across research protocols. Full compound specifications and COA documentation are available upon request from Alpha Tides.
Product Details
- Form: Lyophilized powder blend
- Contents: CJC-1295 10mg + Ipamorelin 10mg per vial
- Total: 20mg per vial
- Purity: 99% per component | COA available on request
- Storage: Keep dry and away from light before reconstitution. Refrigerate after reconstitution.
Research Use Only
CJC-1295 Ipamorelin blend is intended strictly for laboratory research by qualified professionals. It is not FDA approved and is not for human or animal use. By purchasing, the buyer confirms the product will be used solely for in vitro research in compliance with all applicable laws and regulations.
Reviews
There are no reviews yet.